M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 26.19 CNY -0.53% Market Closed
Market Cap: 11.3B CNY
Have any thoughts about
Mayinglong Pharmaceutical Group Co Ltd?
Write Note

Mayinglong Pharmaceutical Group Co Ltd
Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mayinglong Pharmaceutical Group Co Ltd
Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
M
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Minority Interest
ÂĄ126.8m
CAGR 3-Years
-10%
CAGR 5-Years
9%
CAGR 10-Years
0%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Minority Interest
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Minority Interest
ÂĄ575.3m
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
21%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Minority Interest
ÂĄ564.9m
CAGR 3-Years
-1%
CAGR 5-Years
41%
CAGR 10-Years
5%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Minority Interest
ÂĄ20.9m
CAGR 3-Years
-54%
CAGR 5-Years
-32%
CAGR 10-Years
-16%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mayinglong Pharmaceutical Group Co Ltd
Glance View

Market Cap
11.3B CNY
Industry
Pharmaceuticals

In the corridors of China's pharmaceutical industry, Mayinglong Pharmaceutical Group Co Ltd stands out with its roots deeply embedded in history while its branches stretch ambitiously into the future. Founded in 1582 during the Ming Dynasty, this firm has garnered a reputation for its innovative approach to traditional Chinese medicine. The company's evolution from an apothecary serving local communities to a publicly traded enterprise mirrors the dynamic growth of China itself. As the world became increasingly captivated by holistic health solutions, Mayinglong capitalized on its heritage of time-tested remedies, turning ancient formulations into modern products. Their flagship product, Mayinglong Hemorrhoid Ointment, is a renowned success, both domestically and internationally, symbolizing the company's unique ability to blend ancient wisdom with contemporary health needs. Mayinglong's business model thrives on a well-balanced portfolio that includes not only traditional Chinese medicines but also a growing pipeline of innovative pharmaceuticals and healthcare products. Leveraging state-of-the-art technology in their R&D centers, they develop new drugs and therapies that align with both modern health trends and the regulatory demands of global markets. The group's revenue streams are diversified across multiple segments, including over-the-counter products, prescription medications, and personal care items. With a vast distribution network both in China and abroad, Mayinglong benefits from scale and brand recognition. Their strategy is a testament to the harmonious merger of tradition and modernity, driving profitability through a deep understanding of consumer needs paired with scientific innovation.

Intrinsic Value
31.89 CNY
Undervaluation 18%
Intrinsic Value
Price
M

See Also

What is Mayinglong Pharmaceutical Group Co Ltd's Minority Interest?
Minority Interest
126.8m CNY

Based on the financial report for Sep 30, 2024, Mayinglong Pharmaceutical Group Co Ltd's Minority Interest amounts to 126.8m CNY.

What is Mayinglong Pharmaceutical Group Co Ltd's Minority Interest growth rate?
Minority Interest CAGR 10Y
0%

Over the last year, the Minority Interest growth was 1%. The average annual Minority Interest growth rates for Mayinglong Pharmaceutical Group Co Ltd have been -10% over the past three years , 9% over the past five years .

Back to Top